sulforaphane has been researched along with Insulin Resistance in 8 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this work was to compare the influences of sulforaphane (SFN) to those of the standard insulin sensitizer pioglitazone (PIO) on high fructose diet (HFrD)-induced insulin resistance, dyslipidemia, hepatosteatosis, and vascular dysfunction in rats." | 7.91 | Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats. ( Gameil, NM; Shawky, NM; Shehatou, GSG; Suddek, GM, 2019) |
| "Sulforaphane (SFA), a naturally active isothiocyanate compound from cruciferous vegetables used in clinical trials for cancer treatment, was found to possess potency to alleviate insulin resistance." | 7.91 | Sulforaphane Prevents Hepatic Insulin Resistance by Blocking Serine Palmitoyltransferase 3-Mediated Ceramide Biosynthesis. ( Du, M; Lei, X; Li, Y; Ren, F; Teng, W; Xie, S, 2019) |
| " Nevertheless, the vasoprotective role of SFN has not been examined in the setting of obesity characterized by hyperleptinemia and insulin resistance." | 7.83 | Sulforaphane improves dysregulated metabolic profile and inhibits leptin-induced VSMC proliferation: Implications toward suppression of neointima formation after arterial injury in western diet-fed obese mice. ( Gameil, NM; Jun, JY; Pichavaram, P; Segar, L; Shawky, NM; Shehatou, GS; Suddek, GM, 2016) |
| "Sulforaphane (SFN) is a natural antioxidant extracted from the cruciferous vegetables." | 5.72 | Sulforaphane alleviates high fat diet-induced insulin resistance via AMPK/Nrf2/GPx4 axis. ( Gao, Y; Liu, J; Ma, X; Thring, RW; Tong, H; Wu, M; Wu, Q; Zhang, Y; Zhang, Z; Zhu, J, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is characterized by lipotoxicity and ectopic lipid deposition within hepatocytes." | 5.62 | Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis. ( Li, J; Teng, W; Xie, S, 2021) |
| "The purpose of this work was to compare the influences of sulforaphane (SFN) to those of the standard insulin sensitizer pioglitazone (PIO) on high fructose diet (HFrD)-induced insulin resistance, dyslipidemia, hepatosteatosis, and vascular dysfunction in rats." | 3.91 | Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats. ( Gameil, NM; Shawky, NM; Shehatou, GSG; Suddek, GM, 2019) |
| "Sulforaphane (SFA), a naturally active isothiocyanate compound from cruciferous vegetables used in clinical trials for cancer treatment, was found to possess potency to alleviate insulin resistance." | 3.91 | Sulforaphane Prevents Hepatic Insulin Resistance by Blocking Serine Palmitoyltransferase 3-Mediated Ceramide Biosynthesis. ( Du, M; Lei, X; Li, Y; Ren, F; Teng, W; Xie, S, 2019) |
| " Nevertheless, the vasoprotective role of SFN has not been examined in the setting of obesity characterized by hyperleptinemia and insulin resistance." | 3.83 | Sulforaphane improves dysregulated metabolic profile and inhibits leptin-induced VSMC proliferation: Implications toward suppression of neointima formation after arterial injury in western diet-fed obese mice. ( Gameil, NM; Jun, JY; Pichavaram, P; Segar, L; Shawky, NM; Shehatou, GS; Suddek, GM, 2016) |
| "Sulforaphane (SFN) is a natural antioxidant extracted from the cruciferous vegetables." | 1.72 | Sulforaphane alleviates high fat diet-induced insulin resistance via AMPK/Nrf2/GPx4 axis. ( Gao, Y; Liu, J; Ma, X; Thring, RW; Tong, H; Wu, M; Wu, Q; Zhang, Y; Zhang, Z; Zhu, J, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is characterized by lipotoxicity and ectopic lipid deposition within hepatocytes." | 1.62 | Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis. ( Li, J; Teng, W; Xie, S, 2021) |
| "Obesity and insulin resistance are the key factors underlying the etiology of major health problems such as hypertension, diabetes and stroke." | 1.39 | Chronic sulforaphane oral treatment accentuates blood glucose impairment and may affect GLUT3 expression in the cerebral cortex and hypothalamus of rats fed with a highly palatable diet. ( Brum, LM; de Assis, AM; Hansen, F; Moreira, JD; Perry, ML; Riboldi, BP; Souza, CG; Souza, DG; Souza, DO, 2013) |
| "Sulforaphane (SFN) is a compound which is found in cruciferous vegetables and that acts as both a potent antioxidant and regulator of gene expression." | 1.38 | Metabolic effects of sulforaphane oral treatment in streptozotocin-diabetic rats. ( de Assis, AM; de Souza, CG; Perry, ML; Rech, A; Sattler, JA; Souza, DO, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J | 1 |
| Xie, S | 2 |
| Teng, W | 2 |
| Zhang, Y | 2 |
| Wu, Q | 1 |
| Liu, J | 1 |
| Zhang, Z | 1 |
| Ma, X | 1 |
| Zhu, J | 1 |
| Thring, RW | 1 |
| Wu, M | 1 |
| Gao, Y | 1 |
| Tong, H | 1 |
| Shawky, NM | 2 |
| Shehatou, GSG | 1 |
| Suddek, GM | 2 |
| Gameil, NM | 2 |
| Li, Y | 1 |
| Du, M | 1 |
| Lei, X | 1 |
| Ren, F | 1 |
| Souza, CG | 1 |
| Riboldi, BP | 1 |
| Hansen, F | 1 |
| Moreira, JD | 1 |
| Souza, DG | 1 |
| de Assis, AM | 2 |
| Brum, LM | 1 |
| Perry, ML | 2 |
| Souza, DO | 2 |
| Pichavaram, P | 1 |
| Shehatou, GS | 1 |
| Jun, JY | 1 |
| Segar, L | 1 |
| Bahadoran, Z | 1 |
| Tohidi, M | 1 |
| Nazeri, P | 1 |
| Mehran, M | 1 |
| Azizi, F | 1 |
| Mirmiran, P | 1 |
| de Souza, CG | 1 |
| Sattler, JA | 1 |
| Rech, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Consumption of a Lyophilized Nasturtium (Tropaeolum Majus L), on the Insulin Response, Lipid Profile, Antioxidant Capacity and Gene Expression in Pre-diabetic Subjects: Bogotá-Colombia[NCT05346978] | 10 participants (Actual) | Interventional | 2018-06-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for sulforaphane and Insulin Resistance
| Article | Year |
|---|---|
Effect of broccoli sprouts on insulin resistance in type 2 diabetic patients: a randomized double-blind clinical trial.
Topics: Adult; Antioxidants; Blood Glucose; Brassica; Diabetes Mellitus, Type 2; Dietary Supplements; Double | 2012 |
7 other studies available for sulforaphane and Insulin Resistance
| Article | Year |
|---|---|
Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Ceramides; Diet, High-Fat; Hep G2 Cells; Humans; | 2021 |
Sulforaphane alleviates high fat diet-induced insulin resistance via AMPK/Nrf2/GPx4 axis.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Diabetes Mellitus, Type 2; Diet, High-Fat; Ins | 2022 |
Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats.
Topics: Animals; Aorta, Thoracic; Blood Glucose; Body Weight; C-Reactive Protein; Dyslipidemias; Fatty Liver | 2019 |
Sulforaphane Prevents Hepatic Insulin Resistance by Blocking Serine Palmitoyltransferase 3-Mediated Ceramide Biosynthesis.
Topics: Animals; Ceramides; Enzyme Inhibitors; Glucose; Glycogen; Hep G2 Cells; Hepatocytes; Humans; Insulin | 2019 |
Chronic sulforaphane oral treatment accentuates blood glucose impairment and may affect GLUT3 expression in the cerebral cortex and hypothalamus of rats fed with a highly palatable diet.
Topics: Animals; Blood Glucose; Cerebral Cortex; Glucose Transporter Type 3; Humans; Hypothalamus; Insulin R | 2013 |
Sulforaphane improves dysregulated metabolic profile and inhibits leptin-induced VSMC proliferation: Implications toward suppression of neointima formation after arterial injury in western diet-fed obese mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Anticarcinogenic Agents; Anti | 2016 |
Metabolic effects of sulforaphane oral treatment in streptozotocin-diabetic rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dietary Supplements; Gluco | 2012 |